Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | PAR Technology Corporation PAR |
Capital Research Global Investors | 1,818,660 8.400% |
1,818,660 (New Position) |
Filing History |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | PagSeguro Digital Ltd. PAGS |
Capital Research Global Investors | 29,137,666 16.300% |
29,137,666 (New Position) |
Filing History |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | OneSpaWorld Holdings Limited OSW |
Capital Research Global Investors | 4,896,238 7.200% |
4,896,238 (New Position) |
Filing History |
| 2021-02-16 3:58 pm Sale |
2021-02-16 | 13G | Old Dominion Freight Line, Inc. ODFL |
Capital Research Global Investors | 16,974,172 7.200% |
-4,907,810 (-22.43%) |
Filing History |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 22,193,527 12.200% |
189,462 (+0.86%) |
Filing History |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | Granite Construction Incorporated GVA |
Capital Research Global Investors | 3,365,500 7.200% |
3,365,500 (New Position) |
Filing History |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | New Frontier Health Corporation NFH |
Capital Research Global Investors | 12,173,386 9.300% |
12,173,386 (New Position) |
Filing History |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | GW PHARMACEUTICALS PLC GWPH |
Capital Research Global Investors | 44,834,512 12.000% |
44,834,512 (New Position) |
Filing History |
| 2021-02-16 3:53 pm Purchase |
2021-02-16 | 13G | Cenovus Energy Inc. CVE |
Capital Research Global Investors | 145,740,343 11.900% |
2,375,452 (+1.66%) |
Filing History |
| 2021-02-16 3:52 pm Purchase |
2021-02-16 | 13G | Kronos Bio, Inc. KRON |
Capital Research Global Investors | 3,541,573 6.300% |
3,541,573 (New Position) |
Filing History |
| 2021-02-16 3:46 pm Sale |
2021-02-16 | 13G | MercadoLibre, Inc. MELI |
Capital Research Global Investors | 2,885,754 5.800% |
-737,584 (-20.36%) |
Filing History |
| 2021-02-16 3:46 pm Unchanged |
2021-02-16 | 13G | Gilead Sciences, Inc. GILD |
Capital Research Global Investors | 121,672,399 9.700% |
0 (Unchanged) |
Filing History |
| 2021-02-16 3:46 pm Purchase |
2021-02-16 | 13G | Cannae Holdings, Inc. CNNE |
Capital Research Global Investors | 7,467,877 8.100% |
809,118 (+12.15%) |
Filing History |
| 2021-02-16 3:46 pm Sale |
2021-02-16 | 13G | Abbott Laboratories ABT |
Capital Research Global Investors | 86,394,199 4.900% |
-27,295,094 (-24.01%) |
Filing History |
| 2021-02-16 3:46 pm Sale |
2021-02-16 | 13G | AbbVie Inc. ABBV |
Capital Research Global Investors | 37,921,062 2.100% |
-48,681,631 (-56.21%) |
Filing History |
| 2021-02-16 3:46 pm Sale |
2021-02-16 | 13G | CONCHO RESOURCES, INC CXO |
Capital Research Global Investors | 9,112,695 4.600% |
-3,333,002 (-26.78%) |
Filing History |
| 2021-02-16 3:46 pm Purchase |
2021-02-16 | 13G | Alcon Inc. ALC |
Capital Research Global Investors | 6,812,420 1.400% |
6,812,420 (New Position) |
Filing History |
| 2021-02-16 3:46 pm Purchase |
2021-02-16 | 13G | Allakos Inc. ALLK |
Capital Research Global Investors | 6,338,967 12.100% |
952,122 (+17.67%) |
Filing History |
| 2021-02-16 3:46 pm Sale |
2021-02-16 | 13G | ATI Inc. ATI |
Capital Research Global Investors | 0 0.000% |
-6,646,030 (Position Closed) |
Filing History |
| 2021-02-16 3:46 pm Purchase |
2021-02-16 | 13G | Allogene Therapeutics, Inc. ALLO |
Capital Research Global Investors | 12,640,338 9.000% |
6,097,660 (+93.20%) |
Filing History |